Literature DB >> 17149397

Vesicant extravasation part II: Evidence-based management and continuing controversies.

Rita Wickham1, Constance Engelking, Carmel Sauerland, Dominick Corbi.   

Abstract

PURPOSE/
OBJECTIVES: To review the literature, synthesize current recommendations, and discuss remaining controversies regarding vesicant extravasation management. DATA SOURCES: Published evidence-based reports, clinical articles, and anecdotal case reports about antineoplastic and nonantineoplastic vesicant agent management. DATA SYNTHESIS: Prevention of vesicant extravasation sequelae requires knowledge about vesicant extravasation manifestations and differentiation of vesicant extravasation from other local IV site reactions. When evidence is weak or missing, logical application of data-based or empirical management strategies is critical. Actions may include timely administration of subcutaneous or topical antidotes, comfort measures, and surgical interventions to minimize the extent of tissue damage and morbidity should extravasation occur.
CONCLUSIONS: Vesicant extravasation and sequelae constitute a complex patient problem. Clinicians should strive to prevent extravasation or seek to minimize injury should it occur. To this end, clinicians must demonstrate awareness of its risks and use specialized knowledge when administering vesicant agents. IMPLICATIONS FOR NURSING: Nurses who administer vesicant agents should understand the nursing and collaborative actions that should be taken to minimize patient morbidity, pain, and disability.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17149397     DOI: 10.1188/06/ONF.1143-1150

Source DB:  PubMed          Journal:  Oncol Nurs Forum        ISSN: 0190-535X            Impact factor:   2.172


  5 in total

Review 1.  Taxanes: vesicants, irritants, or just irritating?

Authors:  Meagan S Barbee; Taofeek K Owonikoko; R Donald Harvey
Journal:  Ther Adv Med Oncol       Date:  2014-01       Impact factor: 8.168

Review 2.  Management of the extravasation of anti-neoplastic agents.

Authors:  J Boulanger; A Ducharme; A Dufour; S Fortier; K Almanric
Journal:  Support Care Cancer       Date:  2015-02-26       Impact factor: 3.603

3.  Cervical dissecting extravasation of oxaliplatin: A case report.

Authors:  Jorge Hernando; Judit Riera-Arnau; Maria Roca; Alejandro Garcia; Jaume Capdevila
Journal:  Mol Clin Oncol       Date:  2022-01-12

4.  Extravasation of oxaliplatin: an infrequent and irritant toxicity.

Authors:  C Pericay; A López; J R Soler; T Bonfill; E Dotor; E Saigí
Journal:  Clin Transl Oncol       Date:  2009-02       Impact factor: 3.405

Review 5.  Extravasation of antineoplastic agents: prevention and treatments.

Authors:  Rita Boschi; Elena Rostagno
Journal:  Pediatr Rep       Date:  2012-08-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.